The German Breast Group conducts research into breast cancer, developing and implementing its own study concepts.
With the help of additional scientific research projects, we strive to gain further insights into this disease.
Results of a retrospective pooled analysis from three randomized neoadjuvant GBG trials (GeparTrio, GeparQuattro and GeparQuinto) evaluating the impact of post-mastectomy RT (PMRT) after NACT on survival in breast cancer patients have been published in the Annals of Surgical Oncology.
Daten einiger GBG Forschungsprojekte werden beim ESMO 2019 vom 27. September bis 1. Oktober in Barcelona vorgestellt.
Data from two similar randomized phase III trials (LEA GBG51 and CALGB 40503) comparing the efficacy of standard ET versus experimental ET plus bevacizumab as first-line treatment for HR-positive MBC have been published in the European Journal of Cancer
We are glad to inform you that the results of a pooled analysis evaluating fatal events during GBG led breast cancer trials have been published in the Breast Cancer
We are pleased to inform you that the results of the randomised phase II GeparNuevo (GBG 89) study that aimed to investigate the addition of durvalumab, a human monoclonal antibody targeting programmed cell death ligand-1 (PD-L1) to an anthracycline taxane-based neoadjuvant therapy in early triple negative breast cancer (TNBC) have been published in the Annals of Oncology.
Every month, we present an interesting paper.
We are delighted to inform you that our analysis on the utility of the CPS + EG score in triple-negative breast cancer patients has been published in European Journal of Cancer